Dey Issues Advisory

Dey Issues Advisory


NAPA, Calif., Aug. 19 -- Dey L.P., a subsidiary of Mylan Inc. (NASDAQ: MYL) , today issued an advisory regarding two lots of its Albuterol Sulfate Inhalation Solution, 0.083%, unit-dose vials. The lots were on a tractor-trailer that was stolen in McKinney, Texas.


The product's NDC number is 49502-697-29; each carton displays the brand name "DEY" and contains thirty 3ml single-dose vials. The lot numbers are "9FE2" and "9G01." Neither lot was available commercially prior to the theft, and no vial or carton of either lot is part of the legitimate pharmaceutical supply chain. Dey has alerted its distributors and customers.


The products in the stolen cartons could represent a health risk because the required temperature-controlled supply chain may have been broken. Products from these lots should not be dispensed, sold or used.


Anyone who has information regarding this incident, has received suspicious or unsolicited offers for the Albuterol in question or received product from these lots is encouraged to contact the U.S. Food and Drug Administration (FDA) Office of Criminal Investigations at 1-800-551-3989. Patient or customer inquiries for the company should be directed to Dey Customer Service at 1-800-527-4278.


Dey discourages patients from purchasing any medication sold outside of legitimate channels


Dey L.P., a subsidiary of Mylan Inc. (NASDAQ: MYL) , is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies and emergency care medicine. As the U.S. leader in sales of nebulized respiratory medication, Dey puts patients first through its development of innovative and affordable therapies.

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.